# Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

> **NCT02259348** · PHASE2 · TERMINATED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 12 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Myeloid Sarcoma
- Chronic Myelogenous Leukemia (CML)
- Juvenile Myelomonocytic Leukemia (JMML)
- Myelodysplastic Syndrome (MDS)
- Non-Hodgkin Lymphoma (NHL)

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** G-CSF
- **BIOLOGICAL:** Interleukin-2
- **DRUG:** Melphalan
- **DRUG:** Thiotepa
- **DRUG:** Rituximab
- **BIOLOGICAL:** Natural killer cell therapy
- **BIOLOGICAL:** T-cell depleted HPC transplant
- **BIOLOGICAL:** CD45RA-depleted HPC transplant

## Key facts

- **NCT ID:** NCT02259348
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2015-04
- **Final completion:** 2016-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Investigator's decision.
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02259348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02259348, "Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02259348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*